Valanafusp alfa

• CAT Number: I041851
• CAS Number: 1815583-32-4
• Purity: ≥95%

Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) [1].
Valanafusp alfa (HIRMAb-IDUA) binds to the HIR extracellular domain (ECD) with an EC50 of 0.93±0.07 nM[2].
Valanafusp alfa (HIRMAb-IDUA) (0.3 μg/mL; 48 h) reduces glycosoaminoglycan accumulation in Hurler fibroblasts by 70% as compared to healthy fibroblasts[2].
Chronic dosing of Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) has an excellent safety profile at all doses with no clinical, histologic, or laboratory findings, and no effect on glycemic control in plasma or cerebrospinal fluid[1].
Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) is stable, and shows rapid clearance and the high systemic volume of distribution in Rhesus monkeys[1].

Reference

[1]. Boado RJ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009 Oct 26;144(2):135-41.
 [Content Brief]

[2]. Boado RJ, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008 Feb 1;99(2):475-84.
 [Content Brief]